Kuala Lumpur, 26 August 2026 – Investment research houses and institutional equity analysts across Malaysia have reaffirmed positive Buy recommendations and raised target prices on premier medical glove manufacturer Kossan Rubber Industries Berhad, citing the decisive completion of multi-year global healthcare inventory destocking cycles, rising factory utilization rates, and firming average selling prices (ASPs).
The constructive equity research outlook reflects a structural recovery across the global medical examination glove sector. Following several quarters of post-pandemic oversupply and intense price competition from regional manufacturers, excess customer stockpiles across North America, Europe, and Japan have normalized toward pre-pandemic inventory-to-sales ratios. In response, international healthcare distributors and pharmaceutical logistics networks are accelerating replenishment procurement orders, pushing Kossan’s plant capacity utilization rates above 78% compared to cyclical lows of 45% recorded in 2023.
Unlock the Full Article
This article is exclusive to The Ledger Asia Subsribers / PAID members.
Already have an account? Log in here
